Hong Kong Exchange: Nurturing China’s Biotech Valley
Health Advances
SEPTEMBER 15, 2020
… And a Conversation with HKEX’s SVP & Head of China Issuer Services Silvia Chen. By Daniel Huang, Analyst ; Andrew Briggs, Engagement Manager ; Gary Cheng, Vice President. Executive Summary. Today, Hong Kong Exchange (HKEX) is the second-largest market for biotech IPOs only after New York’s NASDAQ, and it has successfully established itself as a first choice IPO destination for China-based biotechs.
Let's personalize your content